Alnylam Pharmaceuticals
Stock Forecast, Prediction & Price Target
Alnylam Pharmaceuticals Financial Estimates
Alnylam Pharmaceuticals Revenue Estimates
Alnylam Pharmaceuticals EBITDA Estimates
Alnylam Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $844.28M N/A | $1.03B 22.87% | $1.82B 76.23% | Avg: $2.34B Low: $2.34B High: $2.34B avg. 28.07% | Avg: $3.18B Low: $3.18B High: $3.18B avg. 36.15% | Avg: $4.00B Low: $4.00B High: $4.00B avg. 25.76% | Avg: $5.06B Low: $5.06B High: $5.06B avg. 26.20% |
Net Income
% change YoY
| $-852.82M N/A | $-1.13B -32.63% | $-440.24M 61.08% | Avg: $-219.55M Low: $-219.55M High: $-219.55M avg. 50.12% | Avg: $283.66M Low: $283.66M High: $283.66M avg. 229.19% | Avg: $700.81M Low: $700.81M High: $700.81M avg. 147.06% | Avg: $1.29B Low: $1.29B High: $1.29B avg. 84.33% |
EBITDA
% change YoY
| $-661.08M N/A | $-740.60M -12.02% | $-228.12M 69.19% | Avg: $-1.69B Low: $-1.69B High: $-1.69B avg. -643.53% | Avg: $-2.30B Low: $-2.30B High: $-2.30B avg. -36.15% | Avg: $-2.90B Low: $-2.90B High: $-2.90B avg. -25.76% | Avg: $-3.66B Low: $-3.66B High: $-3.66B avg. -26.20% |
EPS
% change YoY
| -$7.2 N/A | -$9.3 -29.16% | -$3.52 62.15% | Avg: -$1.76 Low: -$1.76 High: -$1.76 avg. 50.06% | Avg: $2.27 Low: $2.27 High: $2.27 avg. 229.19% | Avg: $5.61 Low: $5.61 High: $5.61 avg. 147.06% | Avg: $10.34 Low: $10.34 High: $10.34 avg. 84.33% |
Operating Expenses
% change YoY
| $1.41B N/A | $1.65B 17.04% | $1.80B 8.85% | Avg: $2.47B Low: $2.47B High: $2.47B avg. 37.55% | Avg: $3.37B Low: $3.37B High: $3.37B avg. 36.15% | Avg: $4.23B Low: $4.23B High: $4.23B avg. 25.76% | Avg: $5.35B Low: $5.35B High: $5.35B avg. 26.20% |
FAQ
What is Alnylam Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 127.68% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is -219.55M, average is -219.55M and high is -219.55M.
What is Alnylam Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 29.04% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $2.34B, average is $2.34B and high is $2.34B.
What is Alnylam Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 127.66% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is -$1.76, average is -$1.76 and high is $-1.75.